These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 26541345)

  • 1. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
    Lowder JN; Taverna P; Issa JP
    Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
    [No Abstract]   [Full Text] [Related]  

  • 2. The euphoria of hypomethylating agents in MDS and AML: is it justified?
    Sekeres MA
    Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
    Estey EH
    Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
    Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
    Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
    [No Abstract]   [Full Text] [Related]  

  • 6. Epigenetic therapies move into new territory, but how exactly do they work?
    Tuma RS
    J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the outlook for myelodysplastic syndrome.
    Brower V
    J Natl Cancer Inst; 2012 Aug; 104(16):1204-6. PubMed ID: 22899627
    [No Abstract]   [Full Text] [Related]  

  • 9. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
    Lübbert M
    Curr Top Microbiol Immunol; 2000; 249():135-64. PubMed ID: 10802943
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.
    Laille E; Shi T; Garcia-Manero G; Cogle CR; Gore SD; Hetzer J; Kumar K; Skikne B; MacBeth KJ
    PLoS One; 2015; 10(8):e0135520. PubMed ID: 26296092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting DNA methylation.
    Issa JP; Kantarjian HM
    Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders.
    Kuykendall JR
    Ann Pharmacother; 2005 Oct; 39(10):1700-9. PubMed ID: 16144884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hypomethylating agents for the treatment of myelodysplastic syndromes].
    Itzykson R; Fenaux P
    Bull Cancer; 2011 Aug; 98(8):927-34. PubMed ID: 21821482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epigenetic therapy in myelodysplastic syndromes].
    Maki K; Mitani K
    Rinsho Ketsueki; 2011 Jul; 52(7):438-46. PubMed ID: 21821974
    [No Abstract]   [Full Text] [Related]  

  • 15. [Demethylating medication in myelodysplastic syndrome].
    Manson ML; Derissen EJ; Wijermans PW; Schellens JH; Beijnen JH
    Ned Tijdschr Geneeskd; 2012; 156(4):A3167. PubMed ID: 22278034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia.
    Voso MT; Lo-Coco F; Fianchi L
    Curr Opin Oncol; 2015 Nov; 27(6):532-9. PubMed ID: 26352541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction.
    Baylin SB; Mufti GJ
    Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S1-3. PubMed ID: 16341235
    [No Abstract]   [Full Text] [Related]  

  • 19. Epigenetic therapy with decitabine for myelodysplasia and leukemia.
    Wijermans P; Lübert M
    Future Oncol; 2005 Oct; 1(5):585-91. PubMed ID: 16556035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decitabine and Cedazuridine.
    Am J Health Syst Pharm; 2020 Oct; 77(22):1809-1811. PubMed ID: 32945859
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.